Issue

2020

Copyright (c) 2020 Ledmar J. Vargas Rodríguez

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Neurocysticercosis: Clinical Case

https://doi.org/10.17081/innosa.90
Marco Antonio Rojas Gutiérrez
Hospital Regional de la Orinoquía, Yopal, Colombia
Stefanía Buitrago Cárdenas
Universidad Rafael Núñez, Cartagena Colombia
Ana Maria Ramos Páez
Universidad Cooperativa de Colombia, Villavicencio, Colombia
Ledmar J. Vargas Rodríguez
Universidad de Boyacá, Tunja, Colombia
https://orcid.org/0000-0001-6001-5720

Corresponding Author(s) : Ledmar J. Vargas Rodríguez

lejovaro@gmail.com

Ciencia e Innovación en Salud, 2020

Abstract

Neurocysticercosis (NCC) is a parasitic infection of the nervous system caused by Taenia Solium. Case report: A 42-year-old patient with headache. The tomography and the resonance can be used with nerocisticercosis, additionally in the ELISA test in CSF it was positive for T. Solium. Discussion: It is a low prevalence entity. It can be classified as parenchymal, subarachnoid, ventricular, spinal and / or mixed. The diagnosis has been oriented from the presence of risk factors, the clinical picture and the imaging findings. The treatment is necessary with albendazole.

Keywords

Cysticercosis, Neurocysticercosis, Taenua solium, brain, central nervous system
1.
Rojas Gutiérrez MA, Buitrago Cárdenas S, Ramos Páez AM, Vargas Rodríguez LJ. Neurocysticercosis: Clinical Case. Ciencia e Innovación en Salud [Internet]. 2020 Sep. 24 [cited 2024 Nov. 13];. Available from: https://revistas.unisimon.edu.co/index.php/innovacionsalud/article/view/3937
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  • Jiménez OH, Nagore N. Endoscopic evidence of ventricular and cisternal inflammatory changes after intraoperative cysticercal rupture during endoscopic third-ventriculostomy removal. Br J Neurosurg. 2013; 27:137– 8. DOI: 10.3109/02688697.2012.703348
  • Clinton A, Coyle C, Rajshekhar V, Singh G, Allen W, Mohanty A, et al. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2017; 66 (15): 49 – 75. DOI: 10.1093/cid/cix1084
  • Astrid Carolina Flórez Sánchez, Sandra Magnolia Pastrán, Nirley Stella Vargas, Mauricio Beltrán, Yamile Enriquez, Adriana Paola Peña, et al. Cisticercosis en Colombia. Estudio de seroprevalencia 2008 – 2010. Acta Neurol Colomb. 2013; 29 (2): 73 - 86. Disponible en: http://www.scielo.org.co/scielo.php?pid=S0120-87482013000200003&script=sci_abstract&tlng=es
  • Moyano LM, O’Neal SE, Ayvar V. Cysticercosis Working Group in Peru. High prevalence of asymptomatic neurocysticercosis in an endemic rural community in Peru. PLoS Negl Trop Dis 2016; 10: e0005130. DOI: 10.1371/journal.pntd.0005130
  • Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 2014; 13:1202–15. DOI: 10.1016/S1474-4422(14)70094-8
  • O’Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003–2012. Emerg Infect Dis 2015; 21:969–76. DOI: 10.3201/eid2106.141324
  • Del Brutto OH, Lama J. The importance of neurocysticercosis in stroke in rural areas of a developing Latin American country. Am J Trop Med Hyg 2013; 89:374–381. DOI: 10.4269/ajtmh.13-0196
  • Hernández RD, Durán BB, Lujambio PS. Magnetic resonance imaging in neurocysticercosis. Top Magn Reson Imaging 2014; 23 (3):191–8. DOI: 10.1097/RMR.0000000000000026
  • Carod JF, Randrianarison M, Razafimahefa J. Evaluation of the performance of 5 commercialized enzyme immunoassays for the detection of Taenia solium antibodies and for the diagnosis of neurocysticercosis. Diagn Microbiol Infect Dis 2012; 72:85–9. DOI: 10.1016/j.diagmicrobio.2011.09.014
  • Del Brutto, O. H., V. Rajshekhar, A. C. White, Jr., V. C. Tsang, T. E. Nash, O. M. Takayanagui, P. M. Schantz, C. A. Evans, A. Flisser, D. Correa, D. Botero, J. C. Allan, E. Sarti, A. E. Gonzalez, R. H. Gilman, and H. H. Garcia. 2001. Proposed diagnostic criteria for neurocysticercosis. Neurology 57:177-183. DOI: 10.1212/wnl.57.2.177
  • Del Brutto, O. H., N. H. Wadia, M. Dumas, M. Cruz, V. C. Tsang, and P. M. Schantz. 1996. Proposal ofdiagnostic criteria for human cysticercosis and neurocysticercosis. J. Neurol. Sci. 142:1-6. DOI: 10.1016/0022-510x(96)00130-x
  • Garcia HH, Evans CA, Nash TE, Takayanagui OM, White AC Jr, Botero D, Rajshekhar V, Tsang VC,Schantz PM, Allan JC, Flisser A, Correa D, Sarti E, Friedland JS, Martinez SM, Gonzalez AE, Gilman RH,Del Brutto OH. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002Oct;15(4):747-56. DOI: 10.1128/CMR.15.4.747-756.2002
  • Serpa JA, Graviss EA, Kass JS, White AC. Neurocysticercosis in Houston, Texas: an update. Medicine(Baltimore) 2011; 90:81–6. DOI: 10.1097/MD.0b013e318206d13e
  • Carrillo Mezo R, Lara García J, Arroyo M, Fleury A. Relevance of 3D magnetic resonance imaging sequencesin diagnosing basal subarachnoid neurocysticercosis. Acta Trop 2015; 152:60. DOI: 10.1016/j.actatropica.2015.08.017
  • Lerner A, Shiroishi MS, Zee CS, Law M, Go JL. Imaging of neurocysticercosis. Neuroimaging Clin N Am2012; 22:659–76. DOI: 10.1016/j.nic.2012.05.004
  • Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci2017; 372:202–10. DOI: 10.1016/j.jns.2016.11.045
  • Garcia HH, Castillo Y, Gonzales I, et al. Low sensitivity and frequent cross-reactions in commercially availableantibody detection ELISA assays for Taenia solium cysticercosis. Trop Med Int Health 2018; 23:101 – 7. DOI: 10.1111/tmi.13010
  • Albenza (albendazole). Product information. Philadelphia, PA: SmithKline Beecham. Disponible en:https://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/207844s000lbl.pdf
  • Garcia HH, Lescano AG, Gonzales I. Cysticercosis Working Group in Peru. Cysticidal efficacy of combinedtreatment with praziquantel and albendazole for parenchymal brain cysticercosis. Clin Infect Dis 2016; 62:1375–9. DOI: 10.1093/cid/ciw134
  • .Romo ML, Wyka K, Carpio A, et al. Ecuadorian Neurocysticercosis Group. The effect of albendazoletreatment on seizure outcomes in patients with symptomatic neurocysticercosis. Trans R Soc Trop Med Hyg2015; 109:738–46. DOI: 10.1093/trstmh/trv078
  • Carpio A, Kelvin EA, Bagiella E. Ecuadorian Neurocysticercosis Group. Effects of albendazole treatment onneurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79:1050–5. DOI: 10.1136/jnnp.2008.144899
  • Solís AM, Tello Chumpitaz TJ, Quinte DH, Ramírez SE. Prevalencia y factores de riesgo asociados aneurocisticercosis en trabajadores del camal Conchucos, El Agustino, Perú. Acta Méd. Peru. 2007; 24 (3):167-171. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1728-59172007000300007
  • Saavedra Herbert, Gonzales Isidro, Alvarado Manuel A., Porras Miguel A., Vargas Victor, Cjuno Román A.et al. Diagnóstico y manejo de la neurocisticercosis en el Perú. Rev. Perú. med. exp. Salud pública [Internet]. 2010 Oct [citado 2020 Jul 19]; 27(4): 586-591. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342010000400015&lng=es
Read More
Author biographies is not available.
Download
PDF HTML

Most read articles by the same author(s)